ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram-Negative Pathogens at ASM Microbe 2018
30 mai 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., May 30, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces First Quarter 2018 Financial Results
10 mai 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y. , May 10, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
11 avr. 2018 09h00 HE
|
ContraFect Corporation
YONKERS, N.Y., April 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
15 mars 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., March 15, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...